癌症治疗中的DNA损伤反应抑制剂:机制,临床开发和组合策略
Seon-Gyeong Lee1, Jinwoo Kim1, Euihwan Jeong1
1CasCure Therapeutics, Seoul 07793, Republic of Korea.
DNA repair
|August 27, 2025
概括
针对DNA损伤反应 (DDR) 途径,包括PARP抑制剂 (PARPi),提供了新的癌症疗法. 这些治疗利用癌细胞的脆弱性诱导瘤死亡,改善患者的治疗结果.
科学领域:
- 癌症学
- 分子生物学
- 遗传学
背景情况:
- 基因组不稳定是癌症的一个关键特征.
- DNA损伤反应 (DDR) 途径保持基因组完整性.
- DDR中的缺陷,如BRCA1/2突变, 造成治疗的脆弱性.
研究的目的:
- 审查PARP抑制剂 (PARPi) 在癌症治疗中的机制.
- 检查PARPi的临床应用和试验.
- 讨论针对DNA修复和检查点的新兴DDR抑制剂.
主要方法:
- 对DDR抑制剂和PARPi的现有文献的审查.
- 对各种DDR抑制剂的作用机制的分析.
- 检查临床试验数据和治疗策略.
主要成果:
- 抑制DNA修复,导致瘤细胞死亡.
- 新兴的DDR抑制剂 (CHK1/2,ATR,ATM,RAD51,APE1,WEE1) 针对DNA修复和检查点.
- 这些抑制剂在癌细胞中诱导复制应激和线索性灾难.
结论:
- 作为独立或组合疗法,DDR抑制剂具有前景.
- 针对DDR提供了一种革命性的癌症治疗方法.
- 挑战包括管理重叠的毒性和保护健康的组织.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
DNA Damage can Stall the Cell Cycle
9.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K


